Multi Institutional Retrospective Study about Median Survival Outcome for Women with Metastatic Triple Negative and HER2 Positive Breast Cancer in Egypt

Abstract

ABSTRACT Metastatic breast cancer (MBC) is still incurable, but it is treatable so goals of therapy are; palliation of symptoms, delay of disease progression, and prolongation of overall survival time without impairing quality of life. Metastatic disease is the main underlying cause of death in the majority of breast cancer patients and represents a great challenge 60 – 70% of breast cancers have estrogen and /or progesterone receptors, 15-20% are HER2 +Ve and Triple -Ve breast cancer make up about 15%. 5-Year survival rates for MBC is 22% as reported by American cancer society. Triple –Ve breast cancer and HER2+Ve are the most aggressive types associated with shortened overall survival. But, now a days survival is greatly improved due to appearance of targeted therapy especially in HER2+Ve breast cancer.